Treats Parkinson's disease (PD). ANDA 201889, held by Alkem Laboratories. Rasagiline Mesylate.
As of Nov 19, 2026, ANDA 201889 (Rasagiline Mesylate), held by Alkem Laboratories, was first approved by FDA on Oct 30, 2017, with 2 approved supplements and 0 published complete response letters.
Rasagiline tablets are indicated for the treatment of Parkinson's disease (PD). Rasagiline tablets, a monoamine oxidase (MAO)-B inhibitor (MAOI), is indicated for the treatment of Parkinson’s disease
| Date | Submission | Status | Documents |
|---|---|---|---|
| Oct 30, 2017 | Original application | Approved | None posted |
| Rasagiline MesylateEQ 0.5MG BASE · tablet;oral | Rasagiline Mesylate | Rx |
| Rasagiline MesylateEQ 1MG BASE · tablet;oral | Rasagiline Mesylate | Rx |
| Jan 14, 2021 | Supplement 4Labeling · Standard review | Approved | None posted |
| Jan 2, 2020 | Supplement 3Labeling · Standard review | Approved | None posted |
| Oct 30, 2017 | Original application | Approved | None posted |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. “What FDA's review says” is read by a model (Claude Haiku) from FDA's summary review PDF; a field is shown only if its numbers appear in the review, and each section links the review. Drugs@FDA and FDA complete response letters